Personnes se prêtant à la recherche : Questions médicales fréquentes
Nom anglais: Research Subjects
Descriptor UI:D035842
Tree Number:M01.774
Termes MeSH sélectionnés :
Double-Blind Method
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Personnes se prêtant à la recherche : Questions médicales les plus fréquentes",
"headline": "Personnes se prêtant à la recherche : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Personnes se prêtant à la recherche : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-25",
"dateModified": "2025-04-19",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Personnes se prêtant à la recherche"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Personnes",
"url": "https://questionsmedicales.fr/mesh/D009272",
"about": {
"@type": "MedicalCondition",
"name": "Personnes",
"code": {
"@type": "MedicalCode",
"code": "D009272",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "M01"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Personnes se prêtant à la recherche",
"alternateName": "Research Subjects",
"code": {
"@type": "MedicalCode",
"code": "D035842",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "None None",
"url": "https://questionsmedicales.fr/author/None%20None",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Stephanie Morain",
"url": "https://questionsmedicales.fr/author/Stephanie%20Morain",
"affiliation": {
"@type": "Organization",
"name": "Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, TX."
}
},
{
"@type": "Person",
"name": "Kemal Hakan Gülkesen",
"url": "https://questionsmedicales.fr/author/Kemal%20Hakan%20G%C3%BClkesen",
"affiliation": {
"@type": "Organization",
"name": "Peter L. Reichertz Institute for Medical Informatics, TU Braunschweig and Hannover Medical School, Braunschweig, Germany."
}
},
{
"@type": "Person",
"name": "Reinhold Haux",
"url": "https://questionsmedicales.fr/author/Reinhold%20Haux",
"affiliation": {
"@type": "Organization",
"name": "Peter L. Reichertz Institute for Medical Informatics, TU Braunschweig and Hannover Medical School, Braunschweig, Germany."
}
},
{
"@type": "Person",
"name": "Sungwoo Um",
"url": "https://questionsmedicales.fr/author/Sungwoo%20Um",
"affiliation": {
"@type": "Organization",
"name": "Department of Ethics Education, Seoul National University, 1, Gwanak-Ro, 11-411, Gwanak-Gu, 08826, South Korea. sungwooum@snu.ac.kr."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Prevention of Radiotherapy-Induced Enteropathy by Probiotics (PREP): Double-Blind Randomized Placebo-Controlled Trial.",
"datePublished": "2024-10-01",
"url": "https://questionsmedicales.fr/article/39451742",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/curroncol31100438"
}
},
{
"@type": "ScholarlyArticle",
"name": "Varenicline and counseling for vaping cessation: a double-blind, randomized, parallel-group, placebo-controlled trial.",
"datePublished": "2023-07-05",
"url": "https://questionsmedicales.fr/article/37403047",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12916-023-02919-2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Sodium Bicarbonate for Metabolic Acidosis in the ICU: Results of a Pilot Randomized Double-Blind Clinical Trial.",
"datePublished": "2023-06-09",
"url": "https://questionsmedicales.fr/article/37294139",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/CCM.0000000000005955"
}
},
{
"@type": "ScholarlyArticle",
"name": "Sodium Bicarbonate Treatment and Vascular Function in CKD: A Randomized, Double-Blind, Placebo-Controlled Trial.",
"datePublished": "2023-05-25",
"url": "https://questionsmedicales.fr/article/37228030",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1681/ASN.0000000000000161"
}
},
{
"@type": "ScholarlyArticle",
"name": "Remote electrical neuromodulation for migraine prevention: A double-blind, randomized, placebo-controlled clinical trial.",
"datePublished": "2023-01-27",
"url": "https://questionsmedicales.fr/article/36704988",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/head.14469"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Personnes",
"item": "https://questionsmedicales.fr/mesh/D009272"
},
{
"@type": "ListItem",
"position": 3,
"name": "Personnes se prêtant à la recherche",
"item": "https://questionsmedicales.fr/mesh/D035842"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Personnes se prêtant à la recherche - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Personnes se prêtant à la recherche",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-11",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Personnes se prêtant à la recherche",
"description": "Comment sont sélectionnés les sujets de recherche ?\nQuels tests sont effectués sur les sujets ?\nLes sujets sont-ils informés des risques ?\nComment évaluer la santé des sujets ?\nQuelles données sont collectées sur les sujets ?",
"url": "https://questionsmedicales.fr/mesh/D035842?mesh_terms=Double-Blind+Method&page=7#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Personnes se prêtant à la recherche",
"description": "Les sujets ressentent-ils des effets secondaires ?\nComment les symptômes sont-ils suivis ?\nLes symptômes varient-ils selon les traitements ?\nLes sujets peuvent-ils signaler des symptômes ?\nY a-t-il un suivi des symptômes après l'étude ?",
"url": "https://questionsmedicales.fr/mesh/D035842?mesh_terms=Double-Blind+Method&page=7#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Personnes se prêtant à la recherche",
"description": "Les sujets reçoivent-ils des conseils préventifs ?\nY a-t-il des vaccinations pour les sujets ?\nComment prévenir les effets indésirables ?\nLes sujets sont-ils formés à la prévention ?\nY a-t-il des recommandations diététiques ?",
"url": "https://questionsmedicales.fr/mesh/D035842?mesh_terms=Double-Blind+Method&page=7#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Personnes se prêtant à la recherche",
"description": "Quels types de traitements sont testés ?\nLes traitements sont-ils randomisés ?\nComment les traitements sont-ils administrés ?\nLes sujets reçoivent-ils un placebo ?\nComment évaluer l'efficacité des traitements ?",
"url": "https://questionsmedicales.fr/mesh/D035842?mesh_terms=Double-Blind+Method&page=7#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Personnes se prêtant à la recherche",
"description": "Quelles complications peuvent survenir ?\nComment sont gérées les complications ?\nLes sujets sont-ils suivis après des complications ?\nLes complications sont-elles documentées ?\nY a-t-il des critères pour signaler des complications ?",
"url": "https://questionsmedicales.fr/mesh/D035842?mesh_terms=Double-Blind+Method&page=7#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Personnes se prêtant à la recherche",
"description": "Quels facteurs de risque sont évalués ?\nLes sujets sont-ils informés des facteurs de risque ?\nComment les facteurs de risque influencent-ils l'étude ?\nLes facteurs de risque sont-ils mesurés ?\nY a-t-il des interventions pour réduire les risques ?",
"url": "https://questionsmedicales.fr/mesh/D035842?mesh_terms=Double-Blind+Method&page=7#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment sont sélectionnés les sujets de recherche ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les sujets sont choisis selon des critères spécifiques liés à l'étude."
}
},
{
"@type": "Question",
"name": "Quels tests sont effectués sur les sujets ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests cliniques, biologiques et d'imagerie peuvent être réalisés."
}
},
{
"@type": "Question",
"name": "Les sujets sont-ils informés des risques ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'information sur les risques est essentielle avant le consentement."
}
},
{
"@type": "Question",
"name": "Comment évaluer la santé des sujets ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des évaluations médicales régulières sont effectuées tout au long de l'étude."
}
},
{
"@type": "Question",
"name": "Quelles données sont collectées sur les sujets ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des données démographiques, cliniques et de réponse au traitement sont collectées."
}
},
{
"@type": "Question",
"name": "Les sujets ressentent-ils des effets secondaires ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des effets secondaires peuvent survenir et doivent être signalés."
}
},
{
"@type": "Question",
"name": "Comment les symptômes sont-ils suivis ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes sont suivis par des questionnaires et des évaluations cliniques."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon les traitements ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier en fonction du traitement administré."
}
},
{
"@type": "Question",
"name": "Les sujets peuvent-ils signaler des symptômes ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les sujets sont encouragés à signaler tout symptôme nouveau ou aggravé."
}
},
{
"@type": "Question",
"name": "Y a-t-il un suivi des symptômes après l'étude ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi peut être proposé pour évaluer les effets à long terme."
}
},
{
"@type": "Question",
"name": "Les sujets reçoivent-ils des conseils préventifs ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des conseils sur la santé et la prévention des maladies peuvent être fournis."
}
},
{
"@type": "Question",
"name": "Y a-t-il des vaccinations pour les sujets ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des vaccinations peuvent être administrées selon les protocoles de l'étude."
}
},
{
"@type": "Question",
"name": "Comment prévenir les effets indésirables ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des mesures préventives et un suivi régulier aident à minimiser les effets indésirables."
}
},
{
"@type": "Question",
"name": "Les sujets sont-ils formés à la prévention ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une formation sur la prévention des maladies peut être incluse dans l'étude."
}
},
{
"@type": "Question",
"name": "Y a-t-il des recommandations diététiques ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recommandations diététiques peuvent être fournies pour améliorer la santé des sujets."
}
},
{
"@type": "Question",
"name": "Quels types de traitements sont testés ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments, des thérapies physiques et des interventions chirurgicales peuvent être testés."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils randomisés ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, de nombreuses études utilisent des méthodes randomisées pour réduire les biais."
}
},
{
"@type": "Question",
"name": "Comment les traitements sont-ils administrés ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements peuvent être administrés par voie orale, intraveineuse ou topique."
}
},
{
"@type": "Question",
"name": "Les sujets reçoivent-ils un placebo ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Dans certaines études, un groupe de sujets peut recevoir un placebo pour comparaison."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'efficacité des traitements ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité est évaluée par des mesures cliniques et des questionnaires standardisés."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications liées aux traitements ou à la maladie peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment sont gérées les complications ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications sont gérées par des interventions médicales appropriées."
}
},
{
"@type": "Question",
"name": "Les sujets sont-ils suivis après des complications ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi est souvent prévu pour évaluer la récupération des sujets."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles documentées ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, toutes les complications doivent être soigneusement documentées dans l'étude."
}
},
{
"@type": "Question",
"name": "Y a-t-il des critères pour signaler des complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des critères spécifiques sont établis pour le signalement des complications."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont évalués ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des facteurs comme l'âge, le sexe, et les antécédents médicaux sont évalués."
}
},
{
"@type": "Question",
"name": "Les sujets sont-ils informés des facteurs de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les sujets reçoivent des informations sur les facteurs de risque associés à l'étude."
}
},
{
"@type": "Question",
"name": "Comment les facteurs de risque influencent-ils l'étude ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent influencer les résultats et la généralisation des conclusions de l'étude."
}
},
{
"@type": "Question",
"name": "Les facteurs de risque sont-ils mesurés ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des questionnaires et des évaluations médicales mesurent les facteurs de risque."
}
},
{
"@type": "Question",
"name": "Y a-t-il des interventions pour réduire les risques ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des interventions peuvent être proposées pour réduire les facteurs de risque identifiés."
}
}
]
}
]
}
Probiotics are thought to be effective in the treatment of radiation-induced enteropathy (RIE). However, little is known regarding their efficacy in preventing RIE. In this prospective, randomized, do...
Vaping cessation is virtually unexplored. The efficacy and safety of varenicline for vaping cessation has not been studied and rigorous research is required to advance best practice and outcomes for p...
Design: Double-blind, randomized, parallel-group, placebo-controlled trial....
The study took place at a University-run smoking cessation center....
People who exclusively use ECs daily and intend to quit vaping....
A total of 140 subjects were randomized to either varenicline (1 mg, administered twice daily for 12 weeks) plus counseling or placebo treatment (administered twice daily, for 12 weeks) plus counselin...
The primary efficacy endpoint of the study was biochemically validated continuous abstinence rate (CAR) at weeks 4 to 12. Secondary efficacy end points were CAR at weeks 4 to 24 and 7-day point preval...
CAR was significantly higher for varenicline vs placebo at each interval: weeks 4-12, 40.0% and 20.0%, respectively (OR = 2.67, 95% CI = [1.25-5.68], P = 0.011); weeks 4-24, 34.3% for varenicline with...
The findings of the present RCT indicate that inclusion of varenicline in a vaping cessation program for people who use electronic cigarettes and intending to quit may result in prolonged abstinence. ...
The study has been registered in EUDRACT with Trial registration ID: 2016-000339-42....
To identify the best population, design of the intervention, and to assess between-group biochemical separation, in preparation for a future phase III trial....
Investigator-initiated, parallel-group, pilot randomized double-blind trial....
Eight ICUs in Australia, New Zealand, and Japan, with participants recruited from April 2021 to August 2022....
Thirty patients greater than or equal to 18 years, within 48 hours of admission to the ICU, receiving a vasopressor, and with metabolic acidosis (pH < 7.30, base excess [BE] < -4 mEq/L, and Pa co2 < 4...
Sodium bicarbonate or placebo (5% dextrose)....
The primary feasibility aim was to assess eligibility, recruitment rate, protocol compliance, and acid-base group separation. The primary clinical outcome was the number of hours alive and free of vas...
The findings confirm the feasibility of a larger phase III sodium bicarbonate trial; eligibility criteria may require modification to facilitate recruitment....
Lower serum bicarbonate levels, even within the normal range, are strongly linked to risks of cardiovascular disease in CKD, possibly by modifying vascular function. In this randomized, controlled tri...
Lower serum bicarbonate levels, even within the normal range, are strongly linked to risks of cardiovascular disease in CKD, possibly by modifying vascular function. Prospective interventional trials ...
We conducted a randomized, double-blind, placebo-controlled trial examining the effect of NaHCO 3 on vascular function in 109 patients with CKD stage 3b-4 (eGFR 15-44 ml/min per 1.73 m 2 ) with normal...
Ninety patients completed this study. After 12 months, plasma bicarbonate levels increased significantly in the NaHCO 3 group compared with placebo (mean [SD] difference between groups 1.35±2.1, P = 0...
Our results do not support the use of NaHCO 3 for vascular dysfunction in participants with CKD and normal serum bicarbonate levels....
To assess the clinical efficacy of remote electrical neuromodulation (REN), used every other day, for the prevention of migraine....
Preventive treatment is key to managing migraine, but it is often underutilized. REN, a non-pharmacological acute treatment for migraine, was evaluated as a method of migraine prevention in patients w...
We conducted a prospective, randomized, double-blind, placebo-controlled, multi-center trial, with 1:1 ratio. The study consisted of a 4-week baseline observation phase, and an 8-week double-blind int...
Two hundred forty-eight participants were randomized (128 active, 120 placebo), of which 179 qualified for the modified intention-to-treat (mITT) analysis (95 active; 84 placebo). REN was superior to ...
Applied every other day, REN is effective and safe for the prevention of migraine....
The aim of this randomized clinical trial was to evaluate the effect of diode laser photobiomodulation (PBM) on post-surgical healing, inflammation and implant stability....
Forty dental implants were inserted into 13 patients. The implants were randomly divided into two groups. The test group (PBM+) underwent two sessions of PBM (combined diode laser of 630 and 808 nm), ...
No differences were found in terms of the mean values of implant stability between the test and control groups over time. Only two of the implants (18.2%) from the PBM- group were classified with the ...
The application of 808 nm infra-red laser for bone tissue, and 630 nm for mucosal tissue in two sessions is considered to be an effective way of reducing inflammation and improving early healing. More...
Chemotherapy can cause hiccups but few randomized controlled trials have focused on hiccups. This trial examined the feasibility of such research....
This single-institution, multi-site trial used phone recruitment for patients: (1) 18 years or older, (2) able to speak/read English, (3) with a working e-mail address, (4) with hiccups 4 weeks prior ...
This trial achieved its primary endpoint of recruiting 20 eligible patients within 5 months; 50 patients were recruited in 3 months. Among the 40 patients who completed the follow-up questionnaire, no...
Clinical trials for chemotherapy-induced hiccups are feasible and could address an unmet need....
Myasthenia gravis (MG) is an autoimmune disease characterized by dysfunction at the neuromuscular junction. Treatment frequently includes corticosteroids (CSs) and IV immunoglobulin (IVIG). This study...
In this randomized double-blind placebo-controlled trial, CS-dependent patients with MG (Myasthenia Gravis Foundation of America Class II-Iva; AChR+) received a loading dose of 2 g/kg IGIV-C over 2 da...
The primary end point (≥50% reduction in CS dose) showed no significant difference between the IGIV-C treatment (60.0% of patients) and placebo (63.3%). There were no significant differences for secon...
In this study, IGIV-C was not more effective than placebo in reducing daily CS dose. These results suggest that the effects of IGIV-C and CS are not synergistic and may be mechanistically different....
The trial was registered on clinicaltrialsregister.eu (EudraCT #: 2013-005099-17) and clinicaltrials.gov (identifier NCT02473965)....
This study provides Class II evidence that IVIG infusions in adult patients with MG do not increase the percentage of patients achieving a ≥50% reduction in corticosteroid dose compared with placebo....
To assess the analgesic efficacy of preoperative gabapentin among patients undergoing dilation and evacuation (D&E) with moderate sedation....
We conducted a randomized, controlled, double-blind trial among patients undergoing same-day D&E at 14 to 19 weeks gestation under moderate sedation. We randomized participants 1:1 to gabapentin 600 m...
We enrolled 126 participants and randomized 61 to gabapentin and 65 to placebo, with study medication administered a mean of 211 (SD 64) minutes preoperatively. Recall of maximum pain was 41 mm for ga...
The addition of gabapentin to moderate sedation during D&E did not result in lower maximum recalled procedural pain. Gabapentin resulted in reduced intra-operative pain during uterine aspiration and i...
Gabapentin reduces intraoperative pain and improves satisfaction with pain management when administered prior to second-trimester surgical abortion and may be considered as an adjunct to intravenous s...
Considering the limitation of varying acid suppression of proton pump inhibitors, this study was aimed to assess the efficacy, safety, and dose-effect relationship of keverprazan, a novel potassium-co...
A randomized, double-blind, double-dummy, multicenter, low-dose, high-dose, and positive-drug parallel-controlled study was conducted to verify the non-inferiority of keverprazan (20 or 30 mg) to lans...
Of the 180 subjects randomized, including 55 cases in the keverprazan_20 mg group, 61 cases in the keverprazan_30 mg group, and 64 cases in the lansoprazole_30 mg group, 168 subjects (93.33%) complete...
Keverprazan was effective and non-inferior to lansoprazole in healing DU. Based on the comparable efficacy and safety data, keverprazan of 20 mg once daily is recommended for the follow-up study of ac...
